LongeVC - an investment group backed by the most prominent advisory board in the longevity industry - has announced its first official early-stage investment fund that is going to be operating in Switzerland and Latvia. This news comes after the announcement of the first exit - Deep Longevity, Inc. has been acquired by the company Regent Pacific (HK: 0575)
Deep Longevity, Inc. provides an integrated platform for the insurance companies, clinicians, hospital networks, and pharmaceutical companies interested in expanding into the emerging field of longevity medicine. It can be used to deploy, integrate, and develop explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. These systems for longevity medicine help physicians to make better decisions on interventions that may slow or reverse aging processes. And Deep Longevity, Inc.'s deep haematological clocks can be explored as a predictive tool for the analysis of COVID-19 positive patients.
Deep Longevity, Inc. provides Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" - it provides a universal multifactorial measure of human biological age to the global network of advanced physicians and researchers. The aging clocks were created in research partnership with one of the most prominent longevity organizations in the world, Human Longevity, Inc.
Deep Longevity, Inc. closed a Series A funding round at the end of June 2020. LongeVC has been joined in a round by some of the most worldwide well-known venture capitalists specializing in biotechnology, longevity, and artificial intelligence ("AI") - ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, co-founder of Oculus, Michael Antonov, and other AI and biotechnology expert investors.
"Our team welcomes this acquisition and is proud to have participated in one of the testimonies to the enormous future potential that the longevity industry has to offer. It is a unique deal for the Baltic area, and we are determined to use our expertise to screen and invest in similar deals globally," explains LongeVC Partner Sergejs Jakimovs.
"There are multiple opportunities in the European Union that may contribute to increasing productive longevity in a very big way while providing a sustainable business model and hefty returns to the medium- and long-term investors. We would like to be one of the first professional venture firms in Europe investing in this area and incubating new companies to fill the niches that are currently underdeveloped to provide substantial opportunities for growth and can be integrated into the growing longevity network", said Garry Zmudze, Managing Partner in LongeVC.
Currently the new fund LongeVC is being set up. The total amount of the money available from the fund is estimated to be USD 35 million. "We are targeting seed stage and pre-A funding round companies as there are limited opportunities worldwide to get investments at these stages. LongeVC will have a strong focus on companies working with solutions in longevity and biotechnology. This is the focus that will drive our interest and not the geographical perspective. LongeVC is already discussing investments with companies from Europe, Asia and the US," says Jakimovs. He also emphasizes that top notch experts in the longevity field are going to be available to startups.
LongeVC is an investment group, specialising in curating, facilitating and executing early stage venture investments in the fields of biotech and longevity. Current investment portfolio of LongeVC includes Insilico Medicine, a global leader in AI-driven drug discovery, Longenesis, an end-to-end collaborative biotech research enabler, Basepaws, the first comprehensive DNA sequencing solution for pets, as well as other biotech industry-specific companies. With its latest exit, LongeVC has announced the creation of its first official early-stage investment fund, focused on biotech and longevity opportunities, with backing from the most prominent advisory board in the longevity industry.
About Regent Pacific
About Regent Pacific
Regent Pacific Group Limited ("Regent Pacific" or the "Company" and together with its subsidiaries, the "Group"; Hong Kong stock code: 00575), a specialist healthcare, wellness and life sciences investment group.
About Deep Longevity, Inc
About Deep Longevity, Inc
Deep Longevity Inc is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological and psychological levels and systems for the emerging field of longevity medicine, enabling physicians to make better decisions on interventions that may slow down or reverse aging processes. The company has developed Longevity as a Service (LaaS)(?) solution to integrate multiple deep biomarkers of aging dubbed "deep aging clocks" which provide a universal multifactorial measure of human biological age. Deep Longevity Inc is the original inventor of deep aging clocks.